Martínez-Vázquez Manuel Alejandro, Bosques-Padilla Francisco J, Miranda-Cordero Rosa María, Yamamoto-Furusho Jesus K
Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud Monterrey, Nuevo León, Mexico.
Departamento de Gastroenterología, Hospital Universitario, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico.
Therap Adv Gastroenterol. 2025 Feb 17;18:17562848251318857. doi: 10.1177/17562848251318857. eCollection 2025.
Inflammatory bowel disease (IBD) is characterized by periods of remission and relapses, and treatment is based on phenotype, risk factors, and disease severity. Treatments include 5-aminosalicylates (5-ASA), thiopurines, methotrexate, calcineurin inhibitors, corticosteroids (CS), biological therapy (BxT), and, more recently, small molecules.
To determine the baseline demographics and clinical characteristics, treatment patterns, and disease status of patients in Mexico with a history of moderate/severe IBD returning for hospital follow-up (Index Day).
This was a non-interventional, cross-sectional study.
Socio-demographics, clinical characteristics, and prescribed treatments were collected from a retrospective review (3 years) of each patient's medical records.
A total of 326 patients with a diagnosis of moderate/severe IBD at least 6 months before the Index Day were included in the analysis: 95 patients (29.2%) had Crohn's disease (CD) and 231 (70.9%) ulcerative colitis (UC). In the CD group, 45.3% ( = 43) had a Harvey Bradshaw Index score ⩾8 or Crohn's Disease Activity Index ⩾220; 10 patients had a B1-non-stenosing, non-penetrating phenotype and 17 had stenosis (B2). In the UC group, 18.2% ( = 42) had moderate/severe disease and the most frequent presentation was pancolitis ( = 56). Regarding treatment over the previous 3 years: for CD, 62 (65.3%) received CS and 20.0% ( = 19) were CS-dependent; 30.5% received 5-ASA + IMS; 27.4% BxT + IMS; and 38.9% 5-ASA + IMS + BxT. In the case of UC, 74.9% ( = 173) received CS and 32.9% ( = 76) were CS-dependent; 64.5% received 5-ASA + IMS; 2.2% BxT + IMS; and 31.6% 5-ASA + IMS + BxT.
In Mexico, 45.3% of CD patients and 18.1% with UC presented with moderate/severe disease activity. Conventional therapy was used to treat the majority of patients, and the availability of more advanced therapies and a personalized treatment approach is needed to improve clinical outcomes in the future.
炎症性肠病（IBD）的特点是有缓解期和复发期，治疗基于疾病表型、危险因素和疾病严重程度。治疗方法包括5-氨基水杨酸类药物（5-ASA）、硫唑嘌呤、甲氨蝶呤、钙调神经磷酸酶抑制剂、皮质类固醇（CS）、生物疗法（BxT），以及最近出现的小分子药物。
确定墨西哥有中度/重度IBD病史且前来医院进行随访（索引日）的患者的基线人口统计学和临床特征、治疗模式及疾病状态。
这是一项非干预性横断面研究。
通过对每位患者的病历进行回顾性分析（3年），收集社会人口统计学、临床特征和所开治疗方法等信息。
共有326例在索引日至少6个月前被诊断为中度/重度IBD的患者纳入分析：95例（29.2%）患有克罗恩病（CD），231例（70.9%）患有溃疡性结肠炎（UC）。在CD组中，45.3%（n = 43）的哈维·布拉德肖指数评分≥8或克罗恩病活动指数≥220；10例患者为B1型非狭窄、非穿透性表型，17例有狭窄（B2型）。在UC组中，18.2%（n = 42）患有中度/重度疾病，最常见的表现是全结肠炎（n = 56）。关于过去3年的治疗情况：对于CD，62例（65.3%）接受了CS治疗，20.0%（n = 19）对CS有依赖；30.5%接受5-ASA + 免疫调节剂（IMS）治疗；27.4%接受BxT + IMS治疗；38.9%接受5-ASA + IMS + BxT治疗。对于UC，74.9%（n = 173）接受了CS治疗，32.9%（n = 76）对CS有依赖；64.5%接受5-ASA + IMS治疗；2.2%接受BxT + IMS治疗；31.6%接受5-ASA + IMS + BxT治疗。
在墨西哥，45.3%的CD患者和18.1%的UC患者存在中度/重度疾病活动。大多数患者采用传统疗法治疗，未来需要有更多先进疗法和个性化治疗方法以改善临床结局。
